David Warr

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 776 citations

Medicine, Pharmacology, Pharmacotherapy +17

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Mark N. Levine, V. Bramwell, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1998 · 623 citations

Medicine, Oncology, Pharmacotherapy +10

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 580 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

Mark N. Levine, J. Hirsh, Michael Gent et al. · The Lancet · 1994 · 513 citations

Pharmacy, Pharmacology, Pharmacotherapy +9

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 465 citations

Medicine, Oncology, Pharmacology +17